Lipid nephrotoxicity: new concept for an old disease (Q37980001)

26 August 2017

Lipid nephrotoxicity: new concept for an old disease (English)

1 reference

26 August 2017

Leonard Gyebi

1

1 reference

PubMed ID

22290079

26 August 2017

Zohreh Soltani

series ordinal

2

1 reference

PubMed ID

22290079

26 August 2017

Efrain Reisin

series ordinal

3

1 reference

26 August 2017

1 April 2012

1 reference

Current Hypertension Reports

26 August 2017

1 reference

26 August 2017

14

1 reference

26 August 2017

2

1 reference

26 August 2017

177-181

1 reference

https://scigraph.springernature.com/pub.10.1007/s11906-012-0250-2

26 August 2017

0 references

cites work

Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

An update on the lipid nephrotoxicity hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Metabolic origins and clinical significance of LDL heterogeneity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Dyslipidemia and the progression of renal disease in chronic renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Lipid abnormalities in uremia, dialysis, and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Diabetes, hemoglobin A(1c), cholesterol, and the risk of moderate chronic renal insufficiency in an ambulatory population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Predictors of new-onset kidney disease in a community-based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Effects of hypertension and dyslipidemia on the decline in renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Effect of the HMG-CoA reductase inhibitor rosuvastatin on early chronic kidney injury in obese zucker rats fed with an atherogenic diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Effect of lipid reduction on the progression of renal disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Rosuvastatin-induced arrest in progression of renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Expression of scavenger receptor CD36 in chronic renal failure patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Modulation of inflammatory mediators and PPARgamma and NFkappaB expression by pravastatin in response to lipoproteins in human monocytes in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

HMG-CoA reductase inhibition aborts functional differentiation and triggers apoptosis in cultured primary human monocytes: a potential mechanism of statin-mediated vasculoprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Treatment of mild to moderate obesity with laparoscopic adjustable gastric banding or an intensive medical program: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Functional and structural renal changes in the early stages of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11906-012-0250-2

Dietary antioxidant inhibits lipoprotein oxidation and renal injury in experimental focal segmental glomerulosclerosis

21 January 2018

1 reference

12 December 2020

Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats

1 reference

12 December 2020

Studies on glomerular basement membrane. II. Isolation and chemical analysis of diseased glomerular basement membrane

1 reference

12 December 2020

Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin

1 reference

12 December 2020

Cholesterol and the risk of renal dysfunction in apparently healthy men.

1 reference

12 December 2020

Atherogenic hyperlipoproteinemia. The cellular and molecular biology of plasma lipoproteins altered by dietary fat and cholesterol.

1 reference

12 December 2020

10.1007/S11906-012-0250-2

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22290079